Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Lulu Wang, Li Li, Rongrong Chen, Xianbo Huang & Xiujin Ye. (2021) Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients. Cancer Management and Research 13, pages 4987-5000.
Read now
Read now
Salvatore Perrone, Fulvio Massaro, Giuliana Alimena & Massimo Breccia. (2016) How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety. Expert Opinion on Pharmacotherapy 17:11, pages 1517-1526.
Read now
Read now
Elias J. Jabbour, Timothy P. Hughes, Jorge E. Cortés, Hagop M. Kantarjian & Andreas Hochhaus. (2014) Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma 55:7, pages 1451-1462.
Read now
Read now
Articles from other publishers (41)
Anna Deregowska, Anna Lewinska, Aleksandra Warzybok, Tomasz Stoklosa & Maciej Wnuk. (2023) Telomere loss is accompanied by decreased pool of shelterin proteins TRF2 and RAP1, elevated levels of TERRA and enhanced glycolysis in imatinib-resistant CML cells. Toxicology in Vitro 90, pages 105608.
Crossref
Crossref
Anna Deręgowska, Monika Pępek, Iwona Solarska, Marcin M. Machnicki, Katarzyna Pruszczyk, Marek Dudziński, Joanna Niesiobędzka-Krężel, Ilona Seferyńska, Waldemar Sawicki, Maciej Wnuk & Tomasz Stokłosa. (2023) The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia. Journal of Cancer Research and Clinical Oncology 149:10, pages 7103-7112.
Crossref
Crossref
Aristidis Tsatsakis, Tatiana Oikonomopoulou, Taxiarchis Nikolouzakis, Elena Vakonaki, Manolis Tzatzarakis, Matthaios Flamourakis, Elisavet Renieri, Persefoni Fragkiadaki, Evaggelia Iliaki, Maria Bachlitzanaki, Vasiliki Karzi, Ioanna Katsikantami, Fotios Kakridonis, Eleftheria Hatzidaki, Maria Tolia, Andrey Svistunov, Demetrios Spandidos, Dragana Nikitovic, John Tsiaoussis & Aikaterini Berdiaki. (2023) Role of telomere length in human carcinogenesis (Review). International Journal of Oncology 63:1.
Crossref
Crossref
Erfan Zaker, Negar Nouri, Sepehr Sorkhizadeh, Hamidreza Ghasemirad, Amir Hossein Hajijafari & Fateme Zare. (2023) The importance of personalized medicine in chronic myeloid leukemia management: a narrative review. Egyptian Journal of Medical Human Genetics 24:1.
Crossref
Crossref
Fábio Morato de Oliveira, Valderez Ravaglio Jamur, Lismeri Wuicik Merfort, Aline Rangel Pozzo & Sabine Mai. (2022) Three-dimensional nuclear telomere architecture and differential expression of aurora kinase genes in chronic myeloid leukemia to measure cell transformation. BMC Cancer 22:1.
Crossref
Crossref
Ali Rafat, Khadijeh Dizaji Asl, Zeinab Mazloumi, Ali Akbar Movassaghpour, Raheleh Farahzadi, Babak Nejati & Hojjatollah Nozad Charoudeh. (2022) Telomerase‐based therapies in haematological malignancies. Cell Biochemistry and Function 40:2, pages 127-140.
Crossref
Crossref
Natalia Estrada, Blanca Xicoy, Fabian Beier, Olga Garcia, Cristian Morales, Concepción Boqué, Miguel Sagüés, Mónica S. Ventura Ferreira, Rolando Vallansot, Sílvia Marcé, Marta Cabezón, Tim H. Brümmendorf & Lurdes Zamora. (2021) Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients. HemaSphere 5:12, pages e657.
Crossref
Crossref
Anna Deregowska, Monika Pepek, Katarzyna Pruszczyk, Marcin M. Machnicki, Maciej Wnuk & Tomasz Stoklosa. (2020) Differential Regulation of Telomeric Complex by BCR-ABL1 Kinase in Human Cellular Models of Chronic Myeloid Leukemia—From Single Cell Analysis to Next-Generation Sequencing. Genes 11:10, pages 1145.
Crossref
Crossref
Lisa Gallicchio, Shahinaz M Gadalla, John D Murphy & Naoko I Simonds. (2018) The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature. JNCI: Journal of the National Cancer Institute 110:10, pages 1048-1058.
Crossref
Crossref
Anne-Sophie BouillonMonica S. Ventura FerreiraShady Adnan AwadJohan RichterAndreas HochhausVolker KunzmannJolanta DenglerJeroen JanssenGert OssenkoppelePeter E. WesterweelPeter A. W. te BoekhorstFrancois-Xavier MahonHenrik Hjorth-HansenSusanne IsfortThoas Fioretos, Sebastian HummelMirle SchemionekStefan WilopSteffen KoschmiederSusanne Saußele, Satu MustjokiFabian BeierTim H. Brümmendorf. (2018) Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. Blood Advances 2:13, pages 1572-1579.
Crossref
Crossref
Balal Brazvan, Abbas Ebrahimi-Kalan, Kobra Velaei, Ahmad Mehdipour, Zeynab Aliyari serej, Ayyub Ebrahimi, Mohammad Ghorbani, Omid Cheraghi & Hojjatollah Nozad Charoudeh. (2018) Telomerase activity and telomere on stem progeny senescence. Biomedicine & Pharmacotherapy 102, pages 9-17.
Crossref
Crossref
Alessandro Allegra, Vanessa Innao, Giuseppa Penna, Demetrio Gerace, Andrea G. Allegra & Caterina Musolino. (2017) Telomerase and telomere biology in hematological diseases: A new therapeutic target. Leukemia Research 56, pages 60-74.
Crossref
Crossref
Theodoros Kelesidis & Ingrid Schmid. (2017) Assessment of Telomere Length, Phenotype, and DNA Content. Current Protocols in Cytometry 79:1.
Crossref
Crossref
Giovanni Caocci, Marianna Greco, Giuseppe Delogu, Christian Secchi, Bruno Martino, Claudia Labate, Elisabetta Abruzzese, Malgorzata Monika Trawinska, Sara Galimberti, Federica Orru, Claudio Fozza, Carlo Gambacorti Passerini, Francesco Galimi & Giorgio La Nasa. (2016) Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients. Journal of Hematology & Oncology 9:1.
Crossref
Crossref
Claudia Bruedigam & Steven W. Lane. (2016) Telomerase in hematologic malignancies. Current Opinion in Hematology 23:4, pages 346-353.
Crossref
Crossref
K Wenn, L Tomala, S Wilop, L Vankann, C Hasenbank, O Frank, A Hochhaus, F J Giles, T Lange, M C Müller, S Koschmieder, F Beier, P Ziegler & T H Brümmendorf. (2015) Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib. Leukemia 29:12, pages 2402-2404.
Crossref
Crossref
Limengmeng Wang, Haowen Xiao, Xing Zhang, Chong Wang & He Huang. (2014) The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation. Journal of Hematology & Oncology 7:1.
Crossref
Crossref
M Braig, N Pällmann, M Preukschas, D Steinemann, W Hofmann, A Gompf, T Streichert, T Braunschweig, M Copland, K L Rudolph, C Bokemeyer, S Koschmieder, A Schuppert, S Balabanov & T H Brümmendorf. (2014) A ‘telomere-associated secretory phenotype’ cooperates with BCR-ABL to drive malignant proliferation of leukemic cells. Leukemia 28:10, pages 2028-2039.
Crossref
Crossref
Marjorie Boissinot, Mathias Vilaine & Sylvie Hermouet. (2014) The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?. Cancers 6:3, pages 1631-1669.
Crossref
Crossref
Oumar Samassekou, Abba Malina, Josée Hébert & Ju Yan. (2013) Presence of alternative lengthening of telomeres associated circular extrachromosome telomere repeats in primary leukemia cells of chronic myeloid leukemia. Journal of Hematology & Oncology 6:1.
Crossref
Crossref
Oumar Samassekou. (2013) Dynamic Length Changes of Telomeres and Their Nuclear Organization in Chronic Myeloid Leukemia. Cancers 5:4, pages 1086-1102.
Crossref
Crossref
Marco Ruella, Silvia Salmoiraghi, Alessandra Risso, Alessandra Carobbio, Stefano Buttiglieri, Tiziana Spatola, Piera Sivera, Irene Ricca, Tiziano Barbui, Corrado Tarella & Alessandro Rambaldi. (2013) Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: A biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy. Experimental Hematology 41:7, pages 627-634.
Crossref
Crossref
Ceri H. Jones, Chris Pepper & Duncan M. Baird. (2012) Telomere dysfunction and its role in haematological cancer. British Journal of Haematology 156:5, pages 573-587.
Crossref
Crossref
Kapil Bhalla, Celalettin Ustun & Warren Fiskus. 2012. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics. Hematologic Cancers: From Molecular Pathobiology to Targeted Therapeutics
277
314
.
Agnes S. M. Yong & Junia V. Melo. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy
259
270
.
Gunhild Keller, Ute Brassat, Melanie Braig, Denise Heim, Henning Wege & Tim H. Brümmendorf. (2009) Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy. Hematological Oncology 27:3, pages 123-129.
Crossref
Crossref
Andrew Proctor, Samantha C. Brownhill & Susan A. Burchill. (2009) The promise of telomere length, telomerase activity and its regulation in the translocation-dependent cancer ESFT; clinical challenges and utility. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792:4, pages 260-274.
Crossref
Crossref
Ulrika Svenson & Göran Roos. (2009) Telomere length as a biological marker in malignancy. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1792:4, pages 317-323.
Crossref
Crossref
F. Beier, S. Balabanov, C.C. Amberger, U. Hartmann, K. Manger, K. Dietz, I. Kötter & T.H. Brummendorf. (2007) Telomere length analysis in monocytes and lymphocytes from patients with systemic lupus erythematosus using multi-color flow-FISH. Lupus 16:12, pages 955-962.
Crossref
Crossref
Mark W. Drummond, Stefan Balabanov, Tessa L. Holyoake & Tim H. Brummendorf. (2007) Concise Review: Telomere Biology in Normal and Leukemic Hematopoietic Stem Cells. Stem Cells 25:8, pages 1853-1861.
Crossref
Crossref
Junia V. Melo & David J. Barnes. (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nature Reviews Cancer 7:6, pages 441-453.
Crossref
Crossref
Peter H. Wiernik. (2006) Plasma cell dyscrasias and leukemias. Update on Cancer Therapeutics 1:4, pages 539-567.
Crossref
Crossref
T H Brümmendorf & S Balabanov. (2006) Telomere length dynamics in normal hematopoiesis and in disease states characterized by increased stem cell turnover. Leukemia 20:10, pages 1706-1716.
Crossref
Crossref
Colleen A. Fordyce, Christopher M. Heaphy, Marco Bisoffi, Jessica L. Wyaco, Nancy E. Joste, Aroop Mangalik, Kathy B. Baumgartner, Richard N. Baumgartner, William C. Hunt & Jeffrey K. Griffith. (2006) Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Research and Treatment 99:2, pages 193-202.
Crossref
Crossref
Irene A.G. Roberts & Inderjeet S. Dokal. 2006. Pediatric Hematology. Pediatric Hematology
384
404
.
Agnes S. M. YongRichard M. SzydloJohn M. GoldmanJane F. ApperleyJunia V. Melo. (2006) Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 107:1, pages 205-212.
Crossref
Crossref
M W Drummond, S F Hoare, A Monaghan, S M Graham, M J Alcorn, W N Keith & T L Holyoake. (2005) Dysregulated expression of the major telomerase components in leukaemic stem cells. Leukemia 19:3, pages 381-389.
Crossref
Crossref
Tim H. Brümmendorf. (2005) Telomerase Activity – a Prognostic Factor in Colorectal Cancer?. Oncology Research and Treatment 28:11, pages 550-551.
Crossref
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 22:4, pages 183-190.
Crossref
Crossref
Ulrike Hartmann, Fabian Beier & Tim H. Brümmendorf. (2004) Telomere length analysis by fluorescence in situ hybridization and flow cytometry (Flow-FISH)/Telomerlängen-Messung mittels Fluoreszenz-in-situ-Hybridisierung und Durchflusszytometrie (Flow-FISH). LaboratoriumsMedizin 28:4, pages 307-316.
Crossref
Crossref
Stephen O'Brien, Ayalew Tefferi & Peter Valent. (2004) Chronic Myelogenous Leukemia and Myeloproliferative Disease. Hematology 2004:1, pages 146-162.
Crossref
Crossref